It is estimated that up to 80% of clinical studies fail to recruit a sufficient number of participants. These failures waste valuable resources and time; delaying new treatments from reaching patients.
Responsible recruitment is supported by our proprietary ”No Patients - No Payment” risk sharing program, through which we give our assurance that your enrolment goals, budgets, and timelines will be met.
The service cost in the active phase is fixed for the agreed number of patients (regardless of additional efforts required to achieve the enrollment target).
Fewer patients enrolled result in lower payments received by Cromos (natural penalty for underenrollment).
More rapid enrollment leads to more rapid receipt of service fee by Cromos for the active phase of the study (natural incentive to enroll fast).
The service budget in the active phase will not change if the number of patients to enroll remains the same.
Find out more about availing of Cromos Pharma’s No Patients No Payment offer by emailing
